Novartis Reports Tumor Cases Linked to Zolgensma Gene Therapy
The drugmaker acknowledges nine tumor reports in children treated with the spinal muscular atrophy therapy, raising safety concerns for gene therapy researchers.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
3 publishers have covered this in 6 articles since 5 Nov 2026. STAT published first, on 5 November at 18:53 UTC; MedPageToday.com - medical news for physicians followed 27h 34m later. The most recent article, from South China Morning Post, appeared on 7 November at 03:35 UTC.
Outlets reporting it: STAT, MedPageToday.com - medical news for physicians, South China Morning Post.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- STATSTAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
- STATSTAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more
- STATSTAT+: Amgen’s Repatha linked to fewer heart attacks
- STATSTAT+: Zolgensma tumor cases show risks of a common gene therapy tool
- MedPageToday.com - medical news for physiciansGene Therapy Under Scrutiny After Nine Tumor Reports
- South China Morning PostUS regulator investigates tumour risk in children given Novartis gene therapy
Sources
Every article we clustered into this story. Headlines link to the publisher.
- US regulator investigates tumour risk in children given Novartis gene therapy South China Morning Post
- Gene Therapy Under Scrutiny After Nine Tumor Reports MedPageToday.com - medical news for physicians
- STAT+: Zolgensma tumor cases show risks of a common gene therapy tool STAT
- STAT+: Amgen’s Repatha linked to fewer heart attacks STAT
- STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more STAT
- STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy STAT
In this story
- Novartis
- Zolgensma